SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76913.50
582.86 (-0.75%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Nectar Lifesciences Ltd.	Q V+ PT	241 Small Cap	12.40 (-1.43%)	N/A	0.35	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Shree Ganesh Remedies Ltd.	Q V PT	661 Small Cap	514.65 (2.72%)	35.53	4.11	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Fabtech Technologies Ltd.	Q V PT	750 Small Cap	168.70 (-1.11%)	31.27	1.94	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Sigachi Industries Ltd.	Q V+ PT	767 Small Cap	20.08 (-0.45%)	N/A	1.64	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Kopran Ltd.	Q V PT	795 Small Cap	164.70 (5.14%)	37.35	1.77	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Anuh Pharma Ltd.	Q V PT	822 Small Cap	81.99 (-0.13%)	19.68	2.42	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Health X Platform Ltd.	Q V PT	884 Small Cap	277.85 (-1.31%)	N/A	3.3	109.13	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Themis Medicare Ltd.	Q V PT	901 Small Cap	97.82 (4.88%)	N/A	2.87	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Wanbury Ltd.	Q V+ PT	901 Small Cap	257.90 (-0.23%)	13.96	7.34	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Fermenta Biotech Ltd.	Q V PT	916 Small Cap	311.40 (-0.43%)	12.78	2.22	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Gujarat Kidney And Super Speciality Ltd.	Q V+ PT	989 Small Cap	125.40 (5.38%)	645.46	N/A	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	3B Blackbio Dx Ltd.	Q V PT	1,036 Small Cap	1,206.60 (-4.77%)	21.28	3.49	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Bajaj Healthcare Ltd.	Q V PT	1,084 Small Cap	322 (-0.45%)	20.81	1.9	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Laxmi Dental Ltd.	Q V PT	1,094 Small Cap	199 (-3.40%)	87.75	4.77	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	GPT Healthcare Ltd.	Q V PT	1,136 Small Cap	138.40 (1.65%)	27.56	4.25	13.96	24.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Tarsons Products Ltd.	Q V+ PT	1,168 Small Cap	219.55 (4.27%)	34.03	1.67	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Syncom Formulations (India) Ltd.	Q V PT	1,291 Small Cap	13.73 (-0.29%)	18.78	3.27	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Lincoln Pharmaceuticals Ltd.	Q V PT	1,293 Small Cap	645.40 (-4.19%)	15.36	1.81	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Hester Biosciences Ltd.	Q V+ PT	1,394 Small Cap	1,638.30 (-1.37%)	39.97	3.94	11.08	0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,412 Small Cap	210.30 (0.69%)	32.55	5.08	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	KMC Speciality Hospitals (India) Ltd.	Q V PT	1,430 Small Cap	87.70 (0.15%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Suraksha Diagnostic Ltd.	Q V PT	1,476 Small Cap	283.45 (0.50%)	44.12	6.18	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Kwality Pharmaceuticals Ltd.	Q V+ PT	1,641 Small Cap	1,581.45 (-0.84%)	29.26	5.39	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Shalby Ltd.	Q V PT	1,732 Small Cap	160.35 (-0.77%)	23.52	1.46	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Windlas Biotech Ltd.	Q V PT	1,800 Small Cap	852.70 (0.05%)	26.97	3.28	18.24	17.22	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Krsnaa Diagnostics Ltd.	Q V PT	1,910 Small Cap	588.65 (1.47%)	23.41	2.01	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Indoco Remedies Ltd.	Q V+ PT	1,937 Small Cap	209.90 (0.33%)	N/A	1.8	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Vimta Labs Ltd.	Q V+ PT	2,043 Small Cap	457.25 (1.55%)	26.92	4.63	13.74	62.65	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Panacea Biotec Ltd.	Q V+ PT	2,214 Small Cap	361.50 (-2.26%)	N/A	7.97	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Morepen Laboratories Ltd.	Q V+ PT	2,269 Small Cap	41.41 (-0.96%)	39.61	1.88	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
RPG Life Sciences	2,297.45	13.59%
Syngene Internation.	467.90	8.30%
Guj. Kidney & Super	125.40	5.38%
Kopran	164.70	5.14%
Aarti Pharmalabs	744.25	4.91%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
3B Blackbio Dx	1,206.60	-4.77%
Lincoln Pharma	645.40	-4.19%
Sun Pharma Adv. Res	142.85	-3.71%
Laxmi Denta	199	-3.40%
Guj. Themis Biosyn	363.75	-3.22%

News about Top Pharma Companies in India

May, 2026

Bajaj Healthcare submits board meeting intimation

Bajaj Healthcare has informed that the meeting of the Board of Directors of the Company is scheduled on 08/05/2026, to consider and approve Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026; and recommend Final Dividend on Equity Shares if any, for the Financial Year 2025-26 subject to the approval of Shareholders of the Company at the ensuing Annual General Meeting of the Company.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), Panacea Biotec has informed that the Income Tax Appellate Tribunal (ITAT) vide its Order dated April 29, 2026, allowed the appeal filed by the Company and set aside the Order dated August 14, 2025 of Commissioner of Income Tax (Appeals) (CIT(A)) arising out of Rectified Assessment Order dated October 10, 2023 passed earlier by Assessing Officer u/s 143(3) read with section 154 of the Income Tax Act, 1961 (Act). As per the aforesaid Rectified Assessment Order dated October 10, 2023, the Assessing Officer raised a demand of ?9.16 Crore for Assessment Year 2020-21 on account of addition of ?3.44 Crore under Section 14A of the Act read with Rule 8D of the Income Tax Rules, 1962. The aforesaid ITAT Order effectively results in deletion of the said disallowances of expenses as well as cancellation of demand of ?9.16 Crore previously raised by Assessing Officer for the Assessment Year 2020- 21. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Wanbury rises as its Patalganga facility completes MFDS inspection successfully

Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules

Apr, 2026

Wanbury’s Patalganga facility completes MFDS inspection successfully

Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules

Apr, 2026

Anuh Pharma informs about press release

Anuh Pharma has informed that the Company has published advertisements in the newspapers Financial Express (English) and Mumbai Lakshdeep (Marathi) editions on Tuesday, 28th April, 2026. This advertisement informs shareholders of Anuh Pharma (‘the Company’) that relate to the initiation of a second phase of 100-day campaign by the Company titled ‘Saksham Niveshak by the Investor Education and Protection Fund Authority (‘IEPFA’), Ministry of Corporate Affairs. Copies of the published advertisements are enclosed herewith. This disclosure is being simultaneously uploaded on the Company’s website: www.anuhpharma.com

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Gujarat Kidney and Super Speciality rises on getting nod to incorporate wholly owned subsidiary

The Board of Directors of the company at their meeting held on April 27, 2026, has approved the same

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	241 Crore
2	Shree Ganesh Remedies Ltd.	661 Crore
3	Fabtech Technologies Ltd.	750 Crore
4	Sigachi Industries Ltd.	767 Crore
5	Kopran Ltd.	795 Crore
6	Anuh Pharma Ltd.	822 Crore
7	Health X Platform Ltd.	884 Crore
8	Themis Medicare Ltd.	901 Crore
9	Wanbury Ltd.	901 Crore
10	Fermenta Biotech Ltd.	916 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,431	54,039	35.46	12.32	24.79	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,192	1,41,859	62.44	15.62	35.30	26.68
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	24.45
Lupin Ltd. (M)	Somewhat Good	2,304	1,05,320	22.67	5.06	13.52	20.83
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
No Yearly Gainers for this list.				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	17.81
Mankind Pharma Ltd. (M)	Very Good	2,247	92,744	54.44	5.81	32.80	14.65
Laurus Labs Ltd. (M)	Very Good	1,099	59,336	66.76	11.20	33.62	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	13.26
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	30.57
Cipla Ltd. (L)	Very Good	1,310	1,05,811	23.27	3.15	14.04	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,808	4,33,848	39.75	5.34	21.73	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Bajaj Healthcare submits board meeting intimation

Panacea Biotec informs about disclosure

Wanbury rises as its Patalganga facility completes MFDS inspection successfully

Wanbury’s Patalganga facility completes MFDS inspection successfully

Anuh Pharma informs about press release

Gujarat Kidney and Super Speciality rises on getting nod to incorporate wholly owned subsidiary

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.